These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 2542806)
1. SR 33557, a novel calcium-antagonist: interaction with [3H]-(+/-)-nitrendipine and [3H]-(-)-desmethoxy-verapamil binding sites in cerebral membranes. Nokin P; Clinet M; Polster P; Beaufort P; Meysmans L; Gougat J; Chatelain P Naunyn Schmiedebergs Arch Pharmacol; 1989; 339(1-2):31-6. PubMed ID: 2542806 [TBL] [Abstract][Full Text] [Related]
2. Identification of a novel calcium antagonist binding site in rat brain by SR 33557. Kenny BA; Fraser S; Spedding M Br J Pharmacol; 1993 Jan; 108(1):93-9. PubMed ID: 7679034 [TBL] [Abstract][Full Text] [Related]
3. SR 33557, a novel calcium entry blocker. II. Interactions with 1,4-dihydropyridine, phenylalkylamine and benzothiazepine binding sites in rat heart sarcolemmal membranes. Nokin P; Clinet M; Beaufort P; Meysmans L; Laruel R; Chatelain P J Pharmacol Exp Ther; 1990 Nov; 255(2):600-7. PubMed ID: 2147036 [TBL] [Abstract][Full Text] [Related]
4. Effects of Ca++ on [3H]diltiazem binding and its allosteric interaction with dihydropyridine calcium channel binding sites in the rat cortex. Schoemaker H; Langer SZ J Pharmacol Exp Ther; 1989 Feb; 248(2):710-5. PubMed ID: 2537412 [TBL] [Abstract][Full Text] [Related]
5. Calcium ions inhibit the allosteric interaction between the dihydropyridine and phenylalkylamine binding site on the voltage-gated calcium channel in heart sarcolemma but not in skeletal muscle transverse tubules. Murphy BJ; Tuana BS Can J Physiol Pharmacol; 1990 Nov; 68(11):1389-95. PubMed ID: 1962734 [TBL] [Abstract][Full Text] [Related]
6. Mechanism of vascular relaxation by thaligrisine: functional and binding assays. Tur R; Magraner J; Catret M; Elorriaga M; Ivorra MD; D'Ocon P; Bermejo A; Cabedo N; Cortes D; Anselmi E Life Sci; 2000 Aug; 67(13):1535-48. PubMed ID: 10983849 [TBL] [Abstract][Full Text] [Related]
7. Evidence for a distinct Ca2+ antagonist receptor for the novel benzothiazinone compound HOE 166. Striessnig J; Meusburger E; Grabner M; Knaus HG; Glossmann H; Kaiser J; Schölkens B; Becker R; Linz W; Henning R Naunyn Schmiedebergs Arch Pharmacol; 1988 Mar; 337(3):331-40. PubMed ID: 2839780 [TBL] [Abstract][Full Text] [Related]
8. Local anesthetics differentiate dihydropyridine calcium antagonist binding sites in rat brain and cardiac membranes. Bolger GT; Marcus KA; Daly JW; Skolnick P J Pharmacol Exp Ther; 1987 Mar; 240(3):922-30. PubMed ID: 3031279 [TBL] [Abstract][Full Text] [Related]
9. Tricyclic antidepressants and calcium channel blockers: interactions at the (-)-desmethoxyverapamil binding site and the serotonin transporter. Rehavi M; Carmi R; Weizman A Eur J Pharmacol; 1988 Oct; 155(1-2):1-9. PubMed ID: 2854066 [TBL] [Abstract][Full Text] [Related]
10. In vitro characterization of a novel Ca2+ entry blocker: SR 33805. Chatelain P; Clinet M; Polster P; Christophe B; Manning AS Eur J Pharmacol; 1993 Aug; 246(3):181-93. PubMed ID: 8223943 [TBL] [Abstract][Full Text] [Related]
11. Ca2+ channel antagonist actions in bladder smooth muscle: comparative pharmacologic and [3H]nitrendipine binding studies. Yousif FB; Bolger GT; Ruzycky A; Triggle DJ Can J Physiol Pharmacol; 1985 May; 63(5):453-62. PubMed ID: 2994869 [TBL] [Abstract][Full Text] [Related]
12. Molecular approach to the calcium channel. Glossmann H; Ferry DR; Goll A; Linn T Adv Myocardiol; 1985; 5():41-76. PubMed ID: 2578683 [TBL] [Abstract][Full Text] [Related]
13. Calcium channel receptor binding studies for diltiazem and its major metabolites: functional correlation to inhibition of portal vein myogenic activity. Schoemaker H; Hicks PE; Langer SZ J Cardiovasc Pharmacol; 1987 Feb; 9(2):173-80. PubMed ID: 2435995 [TBL] [Abstract][Full Text] [Related]
14. Two calcium channels in basolateral membranes of rabbit ileal epithelial cells. Homaidan FR; Donowitz M; Weiland GA; Sharp GW Am J Physiol; 1989 Jul; 257(1 Pt 1):G86-93. PubMed ID: 2473655 [TBL] [Abstract][Full Text] [Related]
15. Characterization of calcium antagonist receptors in highly purified porcine cardiac sarcolemma. Haase H; Wallukat G; Vetter R; Will H Biomed Biochim Acta; 1987; 46(8-9):S363-9. PubMed ID: 2829862 [TBL] [Abstract][Full Text] [Related]
16. Interaction of SR 33557 with skeletal muscle calcium channel blocker receptors in the baboon: characterization of its binding sites. Sol-Rolland J; Joseph M; Rinaldi-Carmona M J Pharmacol Exp Ther; 1991 May; 257(2):595-602. PubMed ID: 1851830 [TBL] [Abstract][Full Text] [Related]
17. Effects of a new dihydropyridine calcium antagonist on vascular smooth muscles, cardiac muscles and [3H]-nitrendipine binding. Miura A; Ukai Y; Matsuzaki T; Taniguchi N; Hayashi S; Kano S; Kimura Y; Kimura K; Enomoto H Arzneimittelforschung; 1986 Sep; 36(9):1323-8. PubMed ID: 3790181 [TBL] [Abstract][Full Text] [Related]
18. Tissue response selectivity of calcium antagonists is not due to heterogeneity of [3H]-nitrendipine binding sites. Bristow MR; Ginsburg R; Laser JA; McAuley BJ; Minobe W Br J Pharmacol; 1984 Jun; 82(2):309-20. PubMed ID: 6329392 [TBL] [Abstract][Full Text] [Related]
19. Diltiazem-like effect of thioridazine on the dihydropyridine binding site of the calcium channel of rat myocardial membranes. Thorgeirsson G; Rudolph SA Biochem Biophys Res Commun; 1984 Jun; 121(2):657-63. PubMed ID: 6329206 [TBL] [Abstract][Full Text] [Related]
20. Correlation between the negative inotropic potency and binding parameters of 1,4-dihydropyridine and phenylalkylamine calcium channel blockers in cat heart. Goll A; Glossmann H; Mannhold R Naunyn Schmiedebergs Arch Pharmacol; 1986 Nov; 334(3):303-12. PubMed ID: 3027587 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]